Chris Ryan | Authors


Tailoring Nivolumab and Ipilimumab Therapy Leads to Better Responses in RCC

September 11, 2022

A more tailored approach to treatment with PD-1 and CTLA-4 immune checkpoint blockade led to improved responses for patients with advanced renal cell carcinoma in both the first- and second-line settings, according to final results from the phase 2 TITAN-RCC trial.

Lasofoxifene Improves Certain Responses in ESR1-Mutated, ER+/HER2- Metastatic Breast Cancer

September 10, 2022

While lasfoxifene alone did not meet the primary end points that researchers set out for it, they did find that it improves responses in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer harboring ESR1 mutations.